Loading...
•
Dec 31, 2022
Caribou Biosciences Q4 2022 Earnings Report
Reported fourth quarter and full year 2022 financial results and provided a business update.
Key Takeaways
Caribou Biosciences reported financial results for the fourth quarter and full year 2022 and reviewed recent pipeline progress. The company had $317.0 million in cash, cash equivalents, and marketable securities as of December 31, 2022, and expects these funds to be sufficient to fund its current operating plan into 2025.
CB-010 ANTLER Phase 1 trial in r/r B-NHL is ongoing with an update planned for H2 2023.
CB-011 CaMMouflage Phase 1 trial in r/r MM is recruiting patients at dose level 1.
CB-012 IND-enabling studies have been initiated, with an IND submission in r/r AML planned for H2 2023.
The company had $317.0 million in cash, cash equivalents, and marketable securities as of December 31, 2022, providing a cash runway to fund the current operating plan into 2025.
Caribou Biosciences
Caribou Biosciences
Forward Guidance
Caribou plans to maintain momentum by advancing two ongoing clinical trials for off-the-shelf cell therapies in patients with hematologic malignancies and preparing an IND submission for its third program, CB-012.
Positive Outlook
- CB-010: Provide an update from the ongoing ANTLER Phase 1 trial for CB-010 in H2 2023.
- CB-011: Provide an update on the clearance of dose levels as appropriate from the CaMMouflage Phase 1 trial for CB-011.
- CB-012: Submit an IND application for CB-012 in H2 2023.